Therapeutic Molecule Phenotypic Screening Capability services in support of USAMRIID

In accordance with Federal Acquisition Regulation (FAR) 15.201 -- Exchange with industry before receipt of proposals and (FAR) 52.215-3 -- Request for information or Solicitation for Planning Purposes this Sources Sought is for information and planning purposes only at this time and shall not be construed as a solicitation or as an obligation or commitment on the part of the Government nor will the Government pay for information solicited. No evaluation letters and/or results will be issued to the respondents. This Sources Sought Notice is not expected to be a Request for Proposal or Invitation for Bid, nor does it restrict the Government to an ultimate acquisition approach. At this time no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS WILL BE ACCEPTED. If a solicitation is released, it will be synopsized on Contract Opportunities at https://beta.sam.gov. It is the responsibility of any potential offeror to monitor this site for the release of any solicitation or synopsis. This Sources Sought Notice is for services to perform assay development and conduct high content screening of therapeutic molecules against SARS-CoV-2 under BSL-3 and BSL-4 conditions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). All responsible parties that feel they can provide the services as documented in the provided attachment should forward their Capability Statement in response to this Sources Sought Notice electronically no later than 1300 Eastern Time (ET) on 17 August 2020 via e-mail to Erik Przygocki at erik.j.przygocki.civ@mail.mil and Jayme L. Fletcher at jayme.l.fletcher2.civ@mail.mil. NO PHONE CALLS WILL BE ACCEPTED.